Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception

Objective:To investigate contraceptive efficacy, compliance and user's satisfaction with transdermal versus oral contraception (OC).Study design: Randomized, open-label, parallel-group trial conducted at 65 centers in Europe and South Africa. One thousand four hundred and eighty-nine women received a contraceptive patch (n = 846) or an OC (n = 643) for 6 or 13 cycles.Results:Overall/method-failure Pearl Indices were 0.88/0.66 with the patch and 0.56/0.28 with the OC (p = n.s.). Compliance was higher at all age groups with the patch compared to the OC. Significantly more users were very satisfied with the contraceptive patch than with the OC. The percentage of patch users being very satisfied increased with age whereas it did not in the OC group. Likewise, improvements of premenstrual symptoms as well as emotional and physical well-being increased with age in the patch-group in contrast to the OC group. Ratings of satisfaction with the study medication correlated weakly with emotional (r = 0.33) and physical well-being (r = 0.39) as well as premenstrual symptoms (r = 0.30; p < 0.001).Conclusion:Contraceptive efficacy of the patch is comparable to OC, but compliance is consistently better at all age groups. Higher satisfaction with the patch at increasing age may be attributed to improvements in emotional and physical well-being as well as reduction of premenstrual symptoms.     

氩激光治疗视网膜中央静脉阻塞

应用氩激光治疗缺血型视网膜中央静脉阻塞(CRVO)30例31只眼．男性23例，女性7例；右眼18例，左眼11例，双眼1例；年龄19～65岁，平均50.54岁．随访时间3~70个月，平均15.9个月．4只眼行格栅栏光稚凝，全部治愈，27只眼行全视网膜光凝，20只眼痊愈，6只眼显效，1只眼有效，没有无效者，井对治疗中的有关问题进行了讨论。 （中华眼底病杂志，1995，11：193-194）     

玻璃体内注射先锋霉素Ⅵ视网膜酶组织化学的实验研究

目的：研究先锋霉素Ⅵ玻璃体腔内注射的安全剂量。 方法：不同浓度的先锋霉素Ⅵ（100、200、250、300、400μg)注入不同组别的兔眼玻璃体腔内，以酶组织化学染色法确定注射后不同时间(1、3、7天)视网膜能量代谢酶琥珀酸脱氢酶(succinic dehydrogenase,SDH)和乳酸脱氢酶(lactic dehydrogenase,LDH)活性的变化并观察视网膜的组织结构及超微结构损害。 结果：随用药剂量增大，视网膜内SDH、LDH活性均逐渐降低；各剂址组活性分别于术后3天和术后1天降至最低，然后开始恢复，至术后7天100、200μg组恢复至正常，其余剂量组仍低于正常.100、200μg剂量组视网膜内仅出现水肿，而250、300、400μg组均出现细胞变性坏死、杆锥体脱失等改变。 结论：先锋霉索Ⅵ玻璃体腔内注射的安全剂量为200μg。 （中华眼底病杂志，1997，13：139-142）     

Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma

Twenty-eight HIV patients either naive or failing highly active antiretroviral therapy (HAART)with moderate-advanced Kaposi's sarcoma (KS)were randomly chosen to initiate a new HAART regimen plus pegylated liposomal doxorubicin(PLD) or the new HAART regimen alone. After 48 weeks, better response rates were observed in the HAART plus PLD group (76% versus 20%).In HIV-infected patients with moderate-advanced KS, HAART alone may not be enough for KS response.